Pfizer Oncology Expands Field Force as Seagen ADC Portfolio Matures

By FieldPulse Editorial · March 8, 2026

Tags: hiring, oncology, pfizer

Pfizer is expanding its oncology field organization to support the growing Seagen ADC portfolio following the completion of commercial integration activities.

Pfizer has been adding oncology field representatives to support its expanded portfolio of antibody-drug conjugates (ADCs) inherited from its Seagen acquisition, as integration of the two commercial organizations continues.

The ADC pipeline — spanning bladder, breast, lymphoma, and cervical cancer indications — has been a central element of Pfizer's oncology growth strategy following the $43 billion acquisition.

Field coverage of the Seagen products has expanded significantly, with Padcev and Adcetris now part of a broader oncology call universe alongside Pfizer's legacy oncology portfolio.

For oncology reps, the integration has meant expanded product responsibilities and more complex territory management.

Training on ADC mechanisms and safety profiles has been a significant focus, with the Seagen scientific reputation giving field teams strong credibility in the accounts that matter most.

Source: https://www.fiercebiotech.com/biotech/pfizer-seagen-integration-complete-600-oncology-reps-2026